<SEC-DOCUMENT>0001144204-17-026318.txt : 20170511
<SEC-HEADER>0001144204-17-026318.hdr.sgml : 20170511
<ACCEPTANCE-DATETIME>20170511112834
ACCESSION NUMBER:		0001144204-17-026318
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170511
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170511
DATE AS OF CHANGE:		20170511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		17833036

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v466768_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 185.85pt 0pt 200.95pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 78.85pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 188.75pt 0pt 200.8pt; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 214.8pt 0pt 227pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 163.15pt 0pt 178.15pt; text-align: center; text-indent: 0.05pt"><B>CURRENT
REPORT Pursuant to</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 163.15pt 0pt 178.15pt; text-align: center; text-indent: 0.05pt"><B>Section 13 or 15(d) of the Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 163.15pt 0pt 178.15pt; text-align: center; text-indent: 0.05pt"><B>Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 79.55pt 0pt 91.55pt; text-align: center"><B>Date of report (Date
of earliest event reported): May 11, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 151.3pt 0pt 163pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>STAAR
Surgical Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 151.3pt 0pt 163pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Exact
Name of Registrant as Specified in Charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0in"><U>Delaware</U></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: center"><U>0-11634</U></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><U>95-3797439</U></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0in">(State or Other Jurisdiction of Incorporation)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(Commission File Number)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: center"><U>1911 Walker Ave., Monrovia, California</U></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center"><U>91016</U></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0in">(Address of Principal Executive Offices)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(Zip Code)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Registrant&rsquo;s Telephone Number, Including
Area Code <U>626-303-7902&#9;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Not Applicable</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>(Former Name or Former Address, if Changed Since
Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 5pt">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I>
General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.2pt 0pt 5pt">Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.6pt 0pt 5pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 11, 2017, STAAR Surgical Company
(the &ldquo;Company&rdquo;) published a press release reporting CE Mark approval for the EVO+ Visian ICL with an aspheric (EDOF)
optic, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;This
information and the information contained in the press release shall not be deemed &ldquo;filed&rdquo; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information
in Item 2.02 of this Current Report, and Exhibit 99.1 are not incorporated by reference into any filings of STAAR made under the
Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation
language in the filing unless specifically stated so therein</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-decoration: underline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 84%; text-decoration: underline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release of the Company dated May 11, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STAAR Surgical Company&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 11, 2017</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 82%; text-decoration: underline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Caren Mason</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.6pt 0pt 5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.6pt 0pt 5pt"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v466768_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Courier; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STAAR Surgical Announces
CE Mark Approval for the </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>EVO+ Visian ICL with Aspheric (EDOF) Optic</B></P>

<P STYLE="font: 10pt Courier; margin: 0pt 0; text-indent: 1.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>MONROVIA, CA,
May 11, 2017</B>--- STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses
and companion delivery systems for the eye, has received CE Mark for its EVO+ Visian ICL&trade; with Aspheric (EDOF) Optic, for
commercialization in the European Union from its Notified Body, DEKRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The EVO+ Visian
ICL with Aspheric (EDOF) Optic is STAAR&rsquo;s next-generation lens. The lens is surgically implanted and works in harmony with
the patient&rsquo;s eye to correct vision. Unlike traditional contact lenses that are placed on the surface of the eye, the EVO
Visian ICL family of lenses is positioned inside the eye between the iris and the natural lens where it stays indefinitely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The EVO+ Visian
ICL with Aspheric (EDOF) Optic is indicated for the correction or reduction of hyperopia and myopia between +3.0 diopters and -18.0
diopters. These lenses include CentraFLOW&reg; technology, a central port that allows the flow of aqueous humor, thus eliminating
the need for peripheral iridotomies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The EVO Visian
ICL family of lenses offers premium refractive outcomes with efficiency and comfort for both the patient and the surgeon. Approximately
285,000 lenses from the EVO Visian ICL product family have been implanted globally to date. Clinical data show that the EVO Visian
ICL provides outstanding, predictable correction of a broad range of refractive errors, with the vast majority of patients achieving
and maintaining 20/20 or better visual acuity through five years of follow up.<SUP>1</SUP> Review of the peer-reviewed published
literature demonstrates an excellent safety profile: specifically, eight studies, including data from 1,291 eyes followed for up
to five years, describe a zero incidence of significant complications.<SUP>2</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;We are very pleased with the CE Mark
approval for the EVO+ Visian ICL with Aspheric (EDOF) Optic. We plan to introduce this lens to a select group of surgeons for <I>Early
Effectiveness Observational </I>use. This beta analysis is designed to elicit surgeon feedback on their experience with the EVO+
Visian ICL with Aspheric (EDOF) Optic including overall performance, patient acceptance, and practice development. This represents
an important new treatment option for eligible patients between 21 and 45 years of age living with nearsightedness or farsightedness.
This approval reinforces our deep commitment to patients seeking visual freedom, as we continue to build our growing EVO Visian
ICL portfolio,&rdquo; said Caren Mason, President and CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Clinical Trial for Presbyopic EVO+ Visian ICL Beginning
this Year</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As reported recently, the first-in-man clinical
trial for the EVO+ Visian ICL lens designed for the correction or reduction of presbyopia is underway and continues to be promising.
&ldquo;Earlier this week, we hosted leading global surgeons at our new STAAR Technology Center, sharing the science behind our
Collamer material technology and early findings of our Presbyopic initial clinical trial. The surgeons were pleased with this <I>investigational
use only</I> preview and impressed with the data. Later this year, we plan to initiate the pivotal clinical trial supporting the
applications for the new EVO+ Visian ICL for correction or reduction of presbyopia,&rdquo; added Ms. Mason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Shimizu K, Kamiya K, Igarashi A, Kobashi H. Long-Term Comparison of Posterior Chamber Phakic Intraocular Lens With and Without
a Central Hole (Hole ICL and Conventional ICL) Implantation for Moderate to High Myopia and Myopic Astigmatism. <I>Medicine. 2016
Apr;95(14):e3270.</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Packer M. Meta-Analysis and Review: Effectiveness, Safety and Central Port Design of the Intraocular Collamer Lens (ICL). <I>Clinical
Ophthalmology, 2016;10;1059-1077.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About STAAR Surgical</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR, which has been dedicated solely to ophthalmic surgery
for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR&rsquo;s lens used in
refractive surgery is called an Implantable Collamer&reg; Lens or &ldquo;ICL&rdquo;. More than 700,000 Visian ICLs have been implanted
to date. To learn more about the ICL go to: www.discovericl.com. STAAR has approximately 336 full-time equivalent employees and
markets lenses in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo,
CA and Monrovia, CA. For more information, please visit the Company&rsquo;s website at www.staar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Safe Harbor</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: any projections or expectations
for sales, marketing and clinical initiatives, success and timing of new or improved products, clinical trials, research and development
activities, performance and significance of a new product, and any statements of assumptions underlying any of the foregoing. Important
additional factors that could cause actual results to differ materially from those indicated by such forward-looking statements
are set forth in the Company&rsquo;s Annual Report on Form 10-K for the year ended December 30, 2016 under the caption &ldquo;Risk
Factors,&rdquo; which is on file with the Securities and Exchange Commission and available in the &ldquo;Investor Information&rdquo;
section of the company&rsquo;s website under the heading &ldquo;SEC Filings.&rdquo; We disclaim any intention or obligation to
update or revise any financial projections or forward-looking statement due to new information or events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are based on expectations and assumptions as
of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited
capital resources and limited access to financing; the negative effect of unstable global economic conditions on sales of products,
such as the EVO Visian ICL product family used in non-reimbursed elective procedures; changes in currency exchange rates; the discretion
of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval
(including but not limited to FDA requirements and/or actions related to the FDA Warning Letter and Form FDA-483s), or to take
enforcement action; research and development efforts may not be successful or may be delayed in delivering products for launch;
the willingness of surgeons and patients to adopt a new or improved product and procedure; and patterns of EVO Visian ICL use that
have typically limited our penetration of the refractive procedure market. The Visian Toric ICL and the Visian ICL with CentraFLOW,
now known as EVO Visian ICL, are not yet approved for sale in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONTACT:</FONT></TD>
    <TD STYLE="width: 89%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investors &amp; Media</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">EVC Group</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Brian Moore, 310-579-6199</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !# 4P# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***,UF
M44A;BF^;Q0 ^BFI)NI<\T +1110 4444 %%%% !1110 4444 %%%% !1110
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M_=3@^Y9=WT<4E?J.2L<__P %%O\ @K+\.O\ @F9>^%(/'>F^*+]_%ZW#6?\
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M[5:&13Y4JR+Q+$P!P_'3ITSYC\8"%_X. ?@WG^+X4:V%]_\ 3(Z8'U/^TO\
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MA7S9IW_!=7X=:1>V%QXX^'OQI^&/A/595BM/%'BCPE-::22QPADD!8Q*<]7
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MR:P@VJ\;%]@C8I,#@\'8Y[UZA_P6D_80^*'_  44^!'A[X>^ ?$7AOPWH_\
M:Z:EKTNJ&;==)$/W,:",'(#,S'/=5K[-I",T!=WN?FQIO_!K+^S2FFV_VRY^
M(TU^D*K--'KP19) HW,%\K@$Y.,UZ#_P1A_X)N_$O_@FA:_$7PMXD\3^'?$7
M@77M3&IZ"ED9A=6<G*-Y@90OSQB(G:?O(?6ON>D"XH"[>Y\+_P#!7'_@EYXR
M_;^^,GP0\3>%=?\ #VD0_#+5S?ZA#J2R[KJ,S028B* C=B(CGU%<M^VA_P $
M<O&-Q^VGH?[07[,_BS0OAOX^\XOXBLM0CE&FZUG[SLL8/^L VRJ1AN&X89K]
M$J* NS,\'RZI-X4TY]<@LK;63;H;Z*SD:2W2;:-XC9@&*;LXR,XQFOC^\^#/
M[9OP(\9Z\G@3XB_#7XJ^$M8OYKZQA\?6US9ZIH@E<MY"S6H*RQ)G"@J"  *^
MTZ*8CY:_8'_8>\8? _XK?$7XM_%?Q3I/BKXL_%(VL6HMHUJ]MI6DV=LFV"TM
MU<EV"YY=N3@5:_;[_89\0_M$^+_ OQ)^&?BZ#P)\8/AA-.VAZG=VINM/O[:<
M!9[&[C!#-#( .0<J17TW2$9H"Y\"_%O]CC]JG]OC0[;P'\;/%/PK\&?"J:YA
ME\16?@F.[GU+Q-%&X<6QEN %@B=E&[ )Q7W;I>B6V@^'K?3K*%;>SL[=+6")
M!Q%&JA54>P  _"KNP4M(#Y:_8H_X)Y1?!O\ 8.U3X*?$M=$\8:9K6HZQ+?QP
MQL;:YMKV[EG1<.,AU61>1T9<@\"KW_!.#]EWXE_L8>$==^'7BCQ7I_C7X=Z'
M=G_A!+^5Y/[8L=/8DBRN]PVOY71'4].#VKZ7HH ^</V]/V#;C]J:_P#"GC3P
M5XKN/AU\8/AU-)/X9\2PP">-4D&);2ZB/$UM)@;E[=17BOC7X$?MQ_M-^$+S
MX?>-O&'P5^'WA'5X6L-;U_PM:7=WJ^HVCC;*D$4^(X&=2022<9XK[YHICN<A
M\!?@QHW[.GP5\+>!/#JW"Z'X1TR#2K$3R>9*8HD"J6;NQQD_6O(_^"8W[(_B
M']B[]GO6/"?B6^TK4-0U#Q=K.OQR:>7,2P7ETTT:G> =X5@#VSTKZ+HH$?(O
M[5G[ _CL_M%?\+Q_9_\ &FE^"/B=>6,>F>(=-UFT:YT'QC:Q?ZH7*(=\<T?1
M94YQQVK,^''P@_;%^,OQ;\-:I\4_B!X ^&W@[PU?)>W&B> 89KJ[\2,N<17%
MQ<KA(#W55R>.>X^S"-U+0.YX?_P47^"OC[]H_P#8]\8> ?AQJNDZ'XC\7VZZ
M6^H:B\BQ6EI(X%RR[ 27,6Y5&,?-7BO@G_@@;\#?!GA+2]+AN_B9&NG6T<&+
M7QKJ-M$2J@$K&D@5 3DX4 #-?;5%(5SY)_X)P?\ !/\ U_\ X)Z?$_XL:%I6
MJVE]\'?%.I0:WX7LIKF6?4M)N6C"W4<K.,,KL P;<2<<UA_M;?LC_':^_P""
M@NA_&_X-WGPSWV'@I_"EQ9^*WNP&+W33F1?(7TVCD^M?:5!YICNSP#]EE_VF
MF\?W?_"YE^#J^&?L1^R_\(FU\;S[5O7&_P \;?+V[NG.<5[_ $ 8HH$%%%%(
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
